TG Therapeutics (FRA:NKB2) Issuance of Debt: €646.7 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NKB2 TG Therapeutics Inc FRA:NKB2
58 GF Score
Price €42.50
GF Value €50.64
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is TG Therapeutics Issuance of Debt?

TG Therapeutics FRA:NKB2 -0.70% 58 Issuance of Debt is €646.7 Mil as of Jun. 2026. GuruFocus rates FRA:NKB2 with a GF Score™ of 58/100 and a GF Value™ of €50.64 (Modestly Undervalued). The stock has 6 warning signs investors should review.

TG Therapeutics's Issuance of Debt for the three months ended in Jun. 2026 was €0.0 Mil.

TG Therapeutics's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was €646.7 Mil.

TG Therapeutics Issuance of Debt Related Terms

TG Therapeutics Issuance of Debt Historical Data

* Premium members only.

The historical data trend for TG Therapeutics's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TG Therapeutics Issuance of Debt Chart

TG Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.95 0.00 22.93 233.80 0.00

TG Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 646.72 0.00
FRA:NKB2
58GF Score
TG Therapeutics Inc FRA:NKB2
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TG Therapeutics Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €646.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of €646.7 Mil mean?
TG Therapeutics (FRA:NKB2) has a Issuance of Debt of €646.7 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on TG Therapeutics and its competitors.
Is TG Therapeutics' Issuance of Debt too high?
TG Therapeutics' current Issuance of Debt is €646.7 Mil. Overall, TG Therapeutics has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' Issuance of Debt compare to PTGX and CRNX?
TG Therapeutics' Issuance of Debt of €646.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on TG Therapeutics and its competitors. TG Therapeutics's current Issuance of Debt is €646.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (FRA:NKB2) is currently considered Modestly Undervalued. The stock's GF Value™ is €50.64, compared to a current price of €42.50 — trading 16.1% below its estimated fair value. The current Issuance of Debt is €646.7 Mil. TG Therapeutics' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For TG Therapeutics (FRA:NKB2), the current Issuance of Debt is €646.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TG Therapeutics (FRA:NKB2) Overvalued in 2026?

Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued. The current stock price of €42.50 is trading 16.1% below its estimated GF Value™ of €50.64. GuruFocus considers TG Therapeutics to be Modestly Undervalued.

Key valuation signals for FRA:NKB2:

  • Issuance of Debt: €646.7 Mil
  • GF Value™: €50.64 vs. price of €42.50 (16.1% below fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the FRA:NKB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TG Therapeutics Business Description

Other Exchanges TGTX:USA1TGTX:Italy
Address 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
58GF Score

Get the complete analysis for FRA:NKB2

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€42.50
Price
€50.64
GF Value